{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.5","upperLimit":"6.0","value":"2.71"}]}]}],"denomUnitsSelected":"sentinel lymph nodes (SLNs)","denoms":[{"counts":[{"groupId":"OG000","value":"5"}],"units":"Participants"},{"counts":[{"groupId":"OG000","value":"17"}],"units":"sentinel lymph nodes (SLNs)"}],"description":"The locations, depth beneath the skin surface and size (measured in three orthogonal dimensions) of each SLN will be recorded - \\[this verbiage comes directly from the protocol\\]","dispersionType":"Full Range","groups":[{"description":"Patients receive perflubutane microbubble injections subdermally and then undergo ultrasound over 30 minutes before standard of care cancer treatment.\n\nPerflubutane Microbubble: Given subdermally\n\nContrast-Enhanced Ultrasound: Undergo ultrasound","id":"OG000","title":"Diagnostic (Perflubutane Microbubble, Ultrasound)"}],"paramType":"MEAN","populationDescription":"Only participants who completed CEUS and surgery (N=5) were analyzed.","reportingStatus":"POSTED","timeFrame":"up to 30 minutes during CEUS procedure","title":"Depth Beneath the Skin Surface of Each SLN","type":"SECONDARY","typeUnitsAnalyzed":"sentinel lymph nodes (SLNs)","unitOfMeasure":"centimeters (cm)"}